➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Baxter
Johnson and Johnson
Harvard Business School
Dow

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,950,049

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,950,049
Title:Composition and therapeutic anti-tumour vaccine
Abstract: The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumor cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of an immune complex with an immunoglobulin, in particular IgG, which recognizes an epitope at the surface of the red blood cells, and/or be heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells. As a variant, the red blood cells may be xenogenic red blood cells. The invention also relates to a therapeutic especially anti-tumor vaccine containing such a composition.
Inventor(s): Godfrin; Yann (Lyons, FR), Banz; Alice (Lyons, FR)
Assignee: ERYTECH PHARMA (Lyons, FR)
Application Number:15/154,273
Patent Claims:1. A method of treating cancer comprising administering to a patient in need thereof an effective amount of a non-naturally-occurring suspension of red blood cells encapsulating a tumor antigen inside of said red blood cells, and an adjuvant for activating dendritic cell maturation.

2. The method of claim 1, comprising inducing in a patient a cytotoxic cellular response against tumor cells or a tumor as a result of administering to said patient an effective amount of the non-naturally-occurring suspension of red blood cells encapsulating a tumor antigen inside of said red blood cells, and the adjuvant for activating dendritic cell maturation.

3. The method according to claim 1, wherein the red blood cells (1) encapsulate said tumor antigen and (2) are in the form of an immune complex with an immunoglobulin which recognizes an epitope at the surface of the red blood cells, so as to promote phagocytosis of said red blood cells by dendritic cells.

4. The method according to claim 3, wherein the red blood cells form an immune complex with an anti-rhesus or anti-glycophorin A or anti-CR1 antibody.

5. The method according to claim 1, wherein the red blood cells (1) encapsulate said tumor antigen and (2) are heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells.

6. The method according to claim 1, wherein the adjuvant is present in the red blood cells, at their surface and/or outside the red blood cells.

7. The method according to claim 6, wherein the adjuvant is a TLR (Toll-like receptor) ligand or a cytokine.

8. The method according to claim 7, wherein the TLR ligand is an imidazoquinoline selected from the group consisting of imidazoquinoline, imiquimod, resiquimod, CpG oligodeoxynucleotides LPSs (lipopolysaccharides) and poly(inosinic acid)-poly(cytidylic acid).

9. The method according to claim 7, wherein the cytokine is selected from the group consisting of interferon alpha, IL-2 (interleukin 2), IFN.gamma. (interferon gamma), GM-CSF (Granulocyte Monocyte-Colony Stimulating Factor), IL-12 (interleukin 12) and TNF.alpha. (Tumor Necrosis Factor alpha).

10. The method according to claim 1, comprising at least two tumour antigens representative of the tumour to be treated.

11. The method according to claim 1, wherein the tumour antigen is an antigen selected from the group consisting of alpha-actinin-4; ARTC1; BCR-ABL fusion protein (b3a2); B-RAF; CASP-5; CASP-8; beta-catenin; Cdc27; CDK4; CDKN2A; COA-1; dek-can fusion protein; EFTUD2; Elongation factor 2; ETV6-AML1 fusion protein; FN1; GPNMB; LDLR-fucosyltransferaseAS fusion protein; HLA-A2d; HLA-A11d; hsp70-2; KIAAO205; MART2; ME1; MUM-1f; MUM-2; MUM-3; neo-PAP; Myosin class I; NFYC; OGT; OS-9; pml-RARalpha fusion protein; PRDX5; PTPRK; K-ras; N-ras; RBAF600; SIRT2; SNRPD1; SYT-SSX1 or -SSX2 fusion protein; Triosephosphate Isomerase; BAGE-1; GAGE-1,2,8; GAGE-3,4,5,6,7; GnTVf; HERV-K-MEL; KK-LC-1; KM-HN-1; LAGE-1; MAGE-A1; MAGE-A2; MAGE-A3; MAGE-A4; MAGE-A6; MAGE-A9; MAGE-A10; MAGE-A12; MAGE-C2; mucin k; NA-88; NY-ESO-1/LAGE-2; SAGE; Sp17; SSX-2; SSX-4; TRAG-3; TRP2-INT2g; CEA; gp100/Pme117; Kallikrein 4; mammagolbulin-A; Melan-A/MART-1; NY-BR-1; OA1; PSA; RAB38/NY-MEL-1; TRP-1/gp75; TRP-2; tyrosinase; adippohilin; AIM-2; BING-4; CPSF; cyclin D1; Ep-CAM; EphA3; FGF5; G250/MN/CAIX; HER-2/neu; IL13Ralpha2; Intestinal carboxyl esterase; alpha-foetoprotein; M-CSF; mdm-2; MMP-2; MUC1; p53; PBF; PRAME; PSMA; RAGE-1; RNF43; RU2AS; secemin 1; SOX10; STEAP1; survivin; Telomerase; WT1; FLT3-ITD; BCLX(L); DKK1; ENAH(hMena); MCSP; RGSS; Gastrin-17; Human Chorionic Gonadotropin; EGFRvIII; HER2; HER2/neu; P501; Guanylyl Cyclase C; and PAP.

12. The method according to claim 1, comprising administering the suspension of red blood cells at a haematocrit level of between 40 and 70%.

13. The method according to claim 1, comprising administering the suspension of red blood cells at a haematocrit level of between 45 and 55%.

14. The method according to claim 1, comprising administering the suspension of red blood cells in a volume of 10 to 250 ml.

15. The method according to claim 1, comprising administering the suspension intravenously by injection or infusion.

16. The method of claim 1, wherein the suspension comprises saline buffer comprising NaCl and an ingredient selected from the group consisting of adenine, glucose and mannitol.

17. The method as claimed in claim 1, wherein the suspension comprises a saline buffer comprising NaCl, adenine, glucose and mannitol.

18. The method as claimed in claim 1, wherein the suspension is packaged into a blood bag suitable for blood transfusion.

19. The method as claimed in claim 1, wherein the blood bag contains the amount of encapsulated tumour antigen corresponding to the medical prescription.

20. The method as claimed in claim 1, wherein the adjuvant is encapsulated inside the red blood cells encapsulating the tumor antigen.

21. The method as claimed in claim 1, wherein the adjuvant is encapsulated inside red blood cells.

22. The method as claimed in claim 1, wherein the suspension comprises a NaCl glucose buffer.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France07 05767Aug 8, 2007

Details for Patent 9,950,049

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 004 1975-06-26   Start Trial ERYTECH PHARMA (Lyons, FR) 2027-08-08 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 006 1975-06-26   Start Trial ERYTECH PHARMA (Lyons, FR) 2027-08-08 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 007 1975-06-26   Start Trial ERYTECH PHARMA (Lyons, FR) 2027-08-08 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 009 1975-06-26   Start Trial ERYTECH PHARMA (Lyons, FR) 2027-08-08 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 010 1975-06-26   Start Trial ERYTECH PHARMA (Lyons, FR) 2027-08-08 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 011 1975-06-26   Start Trial ERYTECH PHARMA (Lyons, FR) 2027-08-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,950,049

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Express Scripts
McKesson
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.